We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
+31.25%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$2.67B
AUM Growth
+$753M
Cap. Flow
-$209M
Cap. Flow %
-7.82%
Top 10 Hldgs %
54.38%
Holding
380
New
93
Increased
88
Reduced
106
Closed
73

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$10.1M
2
CYTR
CytRx Corp
CYTR
+$5.67M
3
CELG
Celgene Corp
CELG
+$4.08M
4
UTHR icon
United Therapeutics
UTHR
+$3.38M
5
DVAX
Dynavax Technologies
DVAX
+$3.33M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$7.47M
2
ABT icon
Abbott
ABT
+$6.5M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$4.84M
4
NVIV
InVivo Therapeutics Holdings Corp
NVIV
+$3.87M
5
AMGN icon
Amgen
AMGN
+$3.54M

Sector Composition

Rank Sector Weight
1 Healthcare 9.24%
2 Consumer Staples 0.04%
3 Technology 0.03%
4 Industrials 0.01%
5 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OCGN icon
276
Ocugen
OCGN
$403M
$151K 0.01%
797
-1,714
-68% -$268K
LUMO
277
PUT
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$150K 0.01%
11
-7
-39% -$695
AKTX
278
Akari Therapeutics
AKTX
$14.4M
$148K 0.01%
22
– –
EVOK
279
DELISTED
Evoke Pharma
EVOK
$144K 0.01%
+443
New +$203K
TNXP icon
280
Tonix Pharmaceuticals
TNXP
$152M
– –
0
– –
ARCT icon
281
PUT
Arcturus Therapeutics
ARCT
$165M
$138K 0.01%
80
+22
+38% +$711
NVIV
282
CALL
DELISTED
InVivo Therapeutics Holdings Corp
NVIV
– –
0
– –
SRNE
283
CALL
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$127K ﹤0.01%
+164
New +$1.1K
RIGL icon
284
CALL
Rigel Pharmaceuticals
RIGL
$723M
$116K ﹤0.01%
32
-136
-81% -$3.9K
PVCT
285
DELISTED
PROVECTUS BIOPHARMACEUTICALS, INC. (DE)
PVCT
$107K ﹤0.01%
1,077,555
+984,272
+1,055% +$215K
ATHX
286
PUT
DELISTED
Athersys, Inc. Common Stock
ATHX
$101K ﹤0.01%
19
+10
+111% +$517
RCKT icon
287
CALL
Rocket Pharmaceuticals
RCKT
$343M
$100K ﹤0.01%
+27
New +$849
GALT icon
288
Galectin Therapeutics
GALT
$230M
$99K ﹤0.01%
87,999
-574,468
-87% -$1.02M
GALT icon
289
PUT
Galectin Therapeutics
GALT
$230M
$93K ﹤0.01%
+825
New +$1.47K
AST
290
CALL
DELISTED
Asterias Biotherapeutics Inc. Series A
AST
$85K ﹤0.01%
+200
New +$647
ZSAN
291
DELISTED
Zosano Pharma Corporation
ZSAN
$82K ﹤0.01%
148
-36
-20% -$28.7K
RXII
292
PUT
DELISTED
GALENA BIOPHARMA INC COM
RXII
$57K ﹤0.01%
1,624
-665
-29% -$23.3K
GPL
293
DELISTED
Great Panther Mining Limited
GPL
$55K ﹤0.01%
+4,045
New +$56.5K
NSPR icon
294
InspireMD
NSPR
$31.4M
$54K ﹤0.01%
+1
New +$104K
FOCL
295
PUT
EDAP TMS S.A.
FOCL
$234M
$53K ﹤0.01%
182
+25
+16% +$76
VKTXW
296
DELISTED
Viking Therapeutics, Inc.
VKTXW
$53K ﹤0.01%
117,008
-59,105
-34% -$26K
DMK
297
PUT
DELISTED
DMK Pharmaceuticals Corporation Common Stock
DMK
$51K ﹤0.01%
+2
New +$416
RXII
298
DELISTED
GALENA BIOPHARMA INC COM
RXII
$49K ﹤0.01%
141,000
+27,470
+24% +$9.55K
ARCT icon
299
Arcturus Therapeutics
ARCT
$165M
$42K ﹤0.01%
2,437
-180
-7% -$5.81K
TENX icon
300
PUT
Tenax Therapeutics
TENX
$393M
– –
0
– –
10 11
12
13 14

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
AB
Aozora Bank Tokyo, Japan $43.6M AUM 1.15% 1-Year Est. Return

Sabby Management's Q3 2016 Portfolio in Review

As of Q3 2016, Sabby Management held 380 positions worth $2.67B, up 39% from $1.92B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Sabby Management withdrew a net $209M in Q3 2016, closing 73 positions and reducing 106 holdings. Its most notable exit was Global Blood Therapeutics, Inc., an estimated $4.84M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 9.2% of assets, down from 13% a quarter earlier, followed by Consumer Staples and Technology.

Against the trend, Sabby Management opened a new position in Bristol-Myers Squibb worth $8.46M.

  • Sabby Management's largest Q3 2016 buy was Bristol-Myers Squibb: 156,887 shares worth $8.46M.
  • Sabby Management added most to Dynavax Technologies in Q3 2016, an estimated $3.33M increase.
  • Sabby Management's biggest Q3 2016 reduction was Sarepta Therapeutics, cutting an estimated $7.47M.
  • Sabby Management fully exited Global Blood Therapeutics, Inc. in Q3 2016, selling an estimated $4.84M.
  • Sabby Management's ten largest holdings make up 54% of its $2.67B portfolio in Q3 2016.
  • Sabby Management opened 93 new positions and closed 73 in Q3 2016.
  • Sabby Management's portfolio value rose 39% quarter-over-quarter to $2.67B.

Based on Sabby Management's 13F filing for Q3 2016, filed 14 Nov 2016.